Background: The significance of uncommon epidermal growth factor receptor (EGFR)
mutations in patients with non-small cell lung cancer (NSCLC) and brain metastasis (BM) …

A small subset of patients with nonsmall cell lung cancer (NSCLC) harbors mutations in the
epidermal growth factor receptor (EGFR) that predict unique sensitivity to EGFR tyrosine …

Brain metastasis (BM) is a leading cause of death in patients with non-small cell lung cancer
(NSCLC). EGFR mutations in primary NSCLC lesions have been associated with sensitivity …

Background Non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor
receptor (EGFR) mutations often develop brain metastases. Treatment with EGFR-tyrosine …

Lung cancer is the leading cause of cancer death in men and women worldwide. Brain
metastasis (BMs) of non-small cell lung cancer (NSCLC) is the most important cause of …

Objective Brain metastases remain lethal in lung cancer patients. The impacts of epidermal
growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitors (TKIs) on the …

Brain metastases are a frequent and grave complication of non-small cell lung carcinoma
(NSCLC). The prognosis is generally poor, despite standard therapy based on surgery and …

Brain metastases are usual in non-small-cell lung cancer (NSCLC) with poor prognosis and
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …

Studies have revealed that non-small cell lung cancer (NSCLC) with epidermal growth factor
receptor (EGFR) mutations has a high incidence of brain metastases (BMs). However, the …

Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …